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TREATMENT OPTIONS FOR POST TREATMENT LYME DISEASE SYNDROME
Barbara Bowman, PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND 58202-9037

Abstract

Literature Review

Discussion

With the high incidence of Lyme disease in the endemic
areas of North America, it is important to appropriately
diagnosis and treat this condition to prevent post treatment
Lyme disease syndrome (PTLDS). Background information
regarding Lyme disease is given. The purpose of this
research is to discuss the treatment options available for
those patients that fit the case definition of PTLDS. A
literature review was conducted using several different
electronic databases finding peer reviewed research
articles pertaining to the treatment options available for
PTLDS. Extended antibiotic use is shown to be not
beneficial in most cases. Alternative treatment options
listed on the internet are shown to be not evidence based.
Therefore, symptomatic treatment options seem to be the
best positive outcome-based option available for providers
to use. These options are discussed in detail throughout
this research. Though much more research is needed
regarding the topic, this will give providers the information
currently available that they will need to know when treating
patients with PTLDS. Hopefully this will provide the
patients with PTLDS the best outcome possible for
improving their quality of life post Lyme disease.

Evidence of PTLDS
 Infectious Diseases Society of America proposed a case
definition for PTLDS in 2006 (Nemeth et al., 2016).
 Middelveen et al. (2018) confirms the presence of live
Borrelia spirochetes with positive cultures in patients who
were treated with antibiotics but remained symptomatic.

 Rebman et al. (2017) found that 59% of participants in the
study with PTLDS were either misdiagnosed or diagnosis was
delayed. This stresses the importance of keeping Lyme
disease in the differential diagnosis for typical symptoms
occurring in endemic areas or those who have travelled to
endemic areas.
 Further research needs to be done to develop more specific
and sensitive lab tests so that concrete diagnoses can be
made when clinical symptoms are not as straight forward as
erythema migrans.

Introduction
 Lyme disease is the most common vector borne illness
in the USA (Rebman et al., 2017).
 Lyme disease is endemic in the Northeast and upper
Midwest states but can also be found along the Pacific
coast (Rebman et al., 2017).
 Presenting symptoms include erythema migrans, Lyme
arthritis, and cranial nerve palsy which are treated with
doxycycline. Hospitalization and IV ceftriaxone are often
required for Lyme carditis and neurologic Lyme disease
other than cranial nerve palsy (DynaMed Plus, Lyme
disease., 2018).
 Misdiagnosis or inappropriate treatment may lead to an
increase in likelihood of developing PTLDS.

Statement of the Problem
Feng et al. (2017) have estimated that approximately 1020% of patients continue suffering from chronic symptoms
described as PTLDS following the standard antibiotic
treatment of 2-4 weeks for early or late Lyme disease. The
question remains that even if these symptoms are a direct
or indirect consequence of Lyme disease, how can
providers appropriately treat these patients.

Research Question
In patients who were treated appropriately for Lyme
disease but develop PTLDS, does extended course
antibiotic therapy versus symptomatic treatment versus
alternative treatments help relieve PTLDS symptoms
most effectively?

Treatment Options
Extended Antibiotic Use
 Studies going back to 2001 but most recently Berende et al.
(2016) have shown that extended use of antibiotics does not
improve symptoms more than the placebo groups
(p=<0.001).
Based on Symptoms
Myalgic encephalomyelitis/chronic fatigue syndrome (CFS)
• Similarities between PTLDS and CFS suggest treatment of
diet, exercise, counseling, acupuncture, and/or off-label use
of methylphenidate may be beneficial (DynaMed Plus,
chronic fatigue syndrome, 2018).
Lyme neuroborreliosis
 With triplicate data sets, Ramesh, Martinez, Martin, &Philipp
(2017) showed that dexamethasone significantly reduced
levels of Borrelia burgdorferi-induced inflammatory cytokines
or chemokines over meloxicam (p<0.05, p<0.01, p<0.001).
Lyme disease-associated facial palsy
• Jowett, Gaudin, Banks, & Hadlock (2017) show worse
outcomes when corticosteroids and antivirals are used with
antibiotics versus monotherapy of antibiotics alone.
Lyme arthritis
 NSAIDS (ibuprofen or naproxen) and DMARDs
(hydroxychloroquine or methotrexate) are shown to be
effective after initial treatment (Arvikar & Steere, 2015)
Alternative Treatments
• Lantos et al. (2015) showed that oxygen therapy, energy and
radiation, metal chelation, nutritional supplements and
biological therapies found on the internet through Google did
not substantiate any efficacy in treatment of Lyme disease.
Essential oils
• Oregano and cinnamon bark showed remarkable activity for
complete eradication of the stationary phase of Borrelia
burgdorferi in animals (Feng et al., 2017).
Supplements
• Nicolson, Settineri, & Ellithorpe (2012) showed a 30.7%
reduction in fatigue within 60 days of using a daily ATP fuel
supplement (p<0.001).

In patients who were treated appropriately for Lyme disease but
develop PTLDS, does extended course antibiotic therapy versus
symptomatic treatment versus alternative treatments help
relieve PTLDS symptoms most effectively?
• Numerous studies have shown that the use of extended
antibiotics is not beneficial and increases the risk of adverse
effects.
• There have been potential studies showing that alternative
therapies may be something of use in the future. Further
research needs to be done to establish the efficacy on
humans.
• That leaves the only option currently available as assessing
every individual patient separately and treating the individual
patient’s symptoms appropriately.
– Fatigue, musculoskeletal pain, and cognitive difficulties are
so similar to CFS that treatment options such as a healthy
diet, exercise, counseling, acupuncture, and/or off-label use
of methylphenidate may be appropriate.
– Dexamethasone for Lyme neuroborreliosis is recommended
except in the case where facial palsy is present.
– NSAIDS and DMARDS can be considered with persistent
Lyme arthritis.

Applicability to Clinical
Practice
 PTLDS case definition (Nemeth et al., 2016, Table 1):
-An adult or child with a documented episode of early or
late Lyme disease
-Treatment with a generally accepted treatment regimen,
with resolution of the objective manifestation
-Onset of any of the following subjective symptoms within
6 months of the diagnosis and persistence of continuous
or relapsing symptoms for at least 6 months after
completion of antibiotic therapy:
 Fatigue, widespread musculoskeletal pain,
complaints of cognitive difficulties, or subjective
symptoms with such severity that, when present, they
result in substantial reduction in previous levels of
occupational, educational, social or personal
activities.
 Extended use of antibiotics should not be prescribed.
Patients must be warned that the efficacy of treatments
listed on the internet are not evidence based and should
be avoided. Treating the patients according to their
symptoms and following the recommended guidelines for
each is the most effective form of treatment for PTLDS as
of now.
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